Boulder BioScience, LLC
Boulder BioScience, LLC, is a privately held biotech firm that has developed a small molecule modulator of the Aryl Hydrocarbon Receptor (AhR). The API is directed to breakthrough clinical use treating Acute Ischemic Stroke (AIS). The API provides protection from hypoxic brain injury and reduces neutrophil and neutrophil extracellular trap (NET) related damage in AIS. Discovery data show that the API intervenes with the inflammatory and thrombotic consequences of AIS ischemic brain injury. Boulder BioScience is seeking to collaborate with pharmaceutical companies to introduce its API and drug products into clinical trials for AIS. Issued and pending patents protect needed formulation technology for the API. The patented oral drug product candidate has passed pre-clinical safety evaluation and is positioned for entry into early-stage clinical trials. The patent pending intravenous drug product candidate has shown remarkable neuroprotective activity in translational models of arterial thrombosis and AIS.
For further information, please email [email protected].